CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Explore how Medicare drug price negotiations under the Inflation Reduction Act could evolve with the Trump administration. Read more here.

The Biden-era law is now in the hands of a new administration, and drugmakers are scanning the horizon for hints of a massive ...

Cleveland-Cliffs and other steel makers rise after President Trump imposes 25% tariffs on imports of steel and aluminum to ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported a larger-than-expected loss for Q1 FY2025, with earnings per share (EPS) at -$1.39, missing the forecast of -$0.39. Revenue also fell short, totaling ...